INTI (Inhibitor Therapeutics) Total Stockholders Equity : $1.99 Mil (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Inhibitor Therapeutics Total Stockholders Equity?

Inhibitor Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $1.99 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Inhibitor Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Inhibitor Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.00.

Inhibitor Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Inhibitor Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibitor Therapeutics Total Stockholders Equity Chart

Inhibitor Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

-3.36

-3.62

8.30

5.28

1.99

Inhibitor Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															5.28	4.64	4.14	3.41	1.99

Inhibitor Therapeutics (OTCPK:INTI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Inhibitor Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1.985	-	0)	/	172.324
	=	0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Inhibitor Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	1.985
	=	0.00

Inhibitor Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibitor Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibitor Therapeutics Inc (OTCPK:INTI) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3014 West Palmira Avenue, Suite 302, Tampa, FL, USA, 33629-7264

Website

https://www.inhibitortx.com

Inhibitor Therapeutics Inc is a pharmaceutical development company that is focused on developing and ultimately commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.

Executives

Black Robe Capital Llc	10 percent owner	900 WEST PLATT STREET SUITE 200, TAMPA FL 33606
Ronald E Osman Irrevocable Trust Iii	10 percent owner	1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959
Ronald E Osman	director, 10 percent owner	1602 KIMMEL STREET, MARION IL 62959
Donovan James Joseph Iii	10 percent owner	C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131
Tpb 2012 Llc	10 percent owner	12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131
Michelle Yanez	director	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Niraj Vasisht	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612
James A Mcnulty	10 percent owner, officer: See Remarks	C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mayne Pharma International Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Ventures Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Group Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Garrison J. Hasara	officer: CFO and Treasurer	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Debra Peattie	director	4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609
Robert Daniel Martin	director	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
E. Brendan Magrab	director, officer: Chairman of the Board	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606